Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Underlying Class | Amount | Exercise Price | Ownership | Footnotes |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
holding | IMNM | Stock Option (Right to Buy) | Oct 2, 2023 | Common Stock | 350K | $1.06 | Direct | F1, F2 |
Id | Content |
---|---|
F1 | 25% of the shares will vest on March 1, 2024, and the remaining shares shall vest in 36 equal monthly installments thereafter. |
F2 | Dr. Turner was appointed as Chief Strategy Officer of the Issuer effective immediately after the Effective Time (as defined in the Agreement and Plan of Merger and Reorganization dated June 29, 2023 (the "Merger Agreement"), by and among the Issuer, Ibiza Merger Sub, Inc., and Morphimmune Inc.). In connection with the Closing (as defined in the Merger Agreement) and prior to Dr. Turner being appointed an executive officer of the Issuer, Dr. Turner exchanged his options to acquire shares of common stock of Morphimmune for options to acquire shares of the Issuer. |
See Attached Exhibit 24